Reply to C. Cremolini et al

[1]  B. Vincenzi,et al.  Predictors of benefit in colorectal cancer treated with cetuximab: are we getting "Lost in TranslationAL"? , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Vandesompele,et al.  Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  P. Laurent-Puig,et al.  KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Manuel Hidalgo,et al.  Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.